Scaling biosolutions from pilot to industrial production
Strategic technology advisory for industrial biotechnology and advanced manufacturing. Supporting founders, investors and boards in aligning technology architecture, capital discipline and industrial execution.
Delivering industrial robustness under capital pressure
Biomanufacturing scale-up is defined by decisions that must withstand operational pressure and capital scrutiny. Process architecture determines cost structure and resilience. Technology choices shape long-term capital logic. Execution discipline determines whether scale translates into sustainable performance.
Operating at the intersection of engineering, capital allocation and organisational design, Koen translates growth ambition into robust industrial systems rather than temporary optimisation gains.
Industrial robustness
Capital clarity
Scalable process architecture
Execution discipline
Trusted by leadership teams and investors across industry
Strategic technology advisory focus areas
Technology strategy, industrial scale-up and capital alignment for biosolutions.
Strategic technology advisory
Defining technology architecture and scale-up pathways that withstand operational complexity and capital scrutiny. From pilot configuration to industrial deployment, aligning process design with long-term cost structure and resilience.
Fractional CTO leadership
Providing executive technical leadership during inflection phases of growth. Building scalable engineering teams, establishing governance structures and ensuring disciplined execution across industrial expansion.
Investor and board advisory
Advising boards and investors on technology risk, capital allocation and operational scalability. Translating scientific ambition into structured industrial roadmaps that support investable growth.
When strategic advisory becomes critical
Industrial biotechnology ventures encounter moments where technology decisions, capital deployment and governance must align. These inflection points often determine whether scale translates into long-term industrial performance.
Pilot to first commercial plant
Transitioning from laboratory success to industrial production introduces irreversible technology and capital decisions. Process architecture, plant configuration and engineering governance must withstand operational complexity.
Capital inflection phases
As companies approach growth equity or strategic investment, clarity around technology scalability and cost structure becomes decisive for investors.
Engineering team expansion
Rapid organisational growth often introduces execution risk. Structured technical leadership ensures engineering capability scales alongside industrial ambition.
Board oversight of technology risk
Boards require independent perspective on scale readiness, capital exposure and execution discipline during periods of accelerated growth.
About Koen Clymans
Koen Clymans is a strategic technology advisor with over two decades of experience in industrial biotechnology, process engineering and scale-up governance. His career spans leadership roles within DSM and Tate & Lyle, as well as advisory and executive positions across high-growth biosolutions ventures. His work centres on strategic technology advisory for industrial biotech platforms navigating scale-up and capital inflection phases.
Operating at the intersection of engineering depth and capital discipline, he supports founders, boards and investors in translating scientific ambition into scalable industrial reality. His work focuses on aligning technology architecture, organisational design and capital allocation to ensure resilient long-term growth.
He currently serves in advisory and steering roles, and is available for board and investment advisory engagements within industrial biosolutions and advanced manufacturing.
Former leadership roles at DSM and Tate & Lyle
Executive and scale-up governance experience
Investor and steering committee advisory roles
Cross-functional engineering and capital alignment
For strategic technology and governance discussions
Engagements are focused on industrial biosolutions, advanced manufacturing and scale-driven technology platforms.